Myrexis, Inc.

Myriad Pharmaceuticals, Inc.

Other

Epicept Corporation

Myriad Genetics, Inc.

Manfredi, John

Mark B Anderson

Warren S Weiner

Rachel M Slade

Yevgeniya Klimova

Ruth J Walton

Robert J Halter

Ashantai J Yungai

Sui Xiong Cai

Kenton Zavitz

Jon Adam Willardsen

Adam Willardsen

Ashok Bajji

Nilantha Sudath Sirisoma

Richard Trovato

Daniel Wettstein

Rajendra Tangallapally

Mark Shenderovich

Se-Ho Kim

Benjamin Markovitz

John A Vanecko

Kazuyuki Suzuki

Hong Zhang

John P Manfredi

Songchun Jiang

Christine A Klein

Andrew Gassman

J Adam Willardsen

Matthew Reeder

Leena Bhoite

Yevgeniya I Klimova

Rachel Slade

The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).

Compounds for Alzheimer's disease

The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(&#x2550;O)OH, -L-CH&#x2550;CHC(&#x2550;O)OH, -L-C(&#x2550;O)NH, -L-C(&#x2550;O)NH(Calkyl), -L-C(&#x2550;O)N(Calkyl), -L-S(&#x2550;O)(Calkyl), -L-S(&#x2550;O)NH, -L-S(&#x2550;O)N(Calkyl), -L-S(&#x2550;O)NH(Calkyl), -L-C(&#x2550;O)NHOH, -L-C(&#x2550;O)CHNH, -L-C(&#x2550;O)CHOH, -L-C(&#x2550;O)CHSH, -L-C(&#x2550;O)NHCN, -L-NHC(&#x2550;O)OR, -L-C(&#x2550;O)NHR, -L-NH(C&#x2550;O)NHR, -L-C(&#x2550;O)N(R), -L-NH(C&#x2550;O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.

The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L, L, are as defined herein.

Purine-core inhibitors of HSP90 and their use in treating cancer

Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Compounds and therapeutical use thereof

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.

Method of treating brain cancer

Novel pyrrole derivatives are disclosed as A&#x3b2;-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the A&#x3b2;peptide.

Pyrrole derivatives as therapeutic compounds

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof

Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof

Compounds for alzheimer's disease

The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.

Therapeutic compounds and their use in cancer

Growing community of inventors

Salt Lake City, UT, United States of America

Mark B Anderson